Safety and Tolerability of Thrombin Inhibition in Scleroderma‐Associated Interstitial Lung Disease

OBJECTIVE: Interstitial lung disease (ILD) is a frequent complication of systemic sclerosis (SSc) (scleroderma) and the leading cause of scleroderma‐related deaths. There exists an unmet need for a new drug therapy for ILD‐complicated SSc. Substantial evidence supports an important role for thrombin...

Descripción completa

Detalles Bibliográficos
Autores principales: Silver, R. M., Wilson, D. A., Akter, T., Atanelishvili, I., Huggins, J. T., Kajdasz, K., Highland, K. B., Nietert, P. J., Bogatkevich, G. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858036/
https://www.ncbi.nlm.nih.gov/pubmed/31777820
http://dx.doi.org/10.1002/acr2.11049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858036/
https://www.ncbi.nlm.nih.gov/pubmed/31777820
http://dx.doi.org/10.1002/acr2.11049

Ejemplares similares